// App-Quantinova.ai

CT108 : Preliminary results

Researchers

Presenter

  • Hope S. Rugo

Principal Investigators

  • J. Thad Beck

  • Guy Jerusalem

  • Hans Wildiers

  • Peter Kabos

  • Michael Chisamore

  • Rhian McNaughton

  • Yanyun Chen

  • Anwar Hossain

  • Sara M. Tolaney

Medical Centers

  • Department of Pathology, University of California, San Francisco, CA

  • Highlands Oncology Group, Fayetteville, AR

  • CHU and Liege University, Domaine du Sart Tilman, Liege, Belgium

  • Department of Medicine, Division of Rheumatology, University of Michigan School of Medicine, Ann Arbor, MI

  • Merck & Co., Inc., Kenilworth, NJ

  • Eli Lilly and Company, Erl Wood, United Kingdom

  • Eli Lilly and Company, Indianapolis, IN

  • Dana-Farber Cancer Institute, Boston, MA

Locations

  • United States

  • Belgium

  • United Kingdom

Companies

  • N/A

Study Components

Therapeutic Area

  • N/A

Disease

  • N/A

Biomarkers

  • Cyclin-dependent kinase 4

  • erb-b2 receptor tyrosine kinase 2

Drug/Treatment

  • Pembrolizumab

  • Abemaciclib

  • Anastrozole

Outcome

  • N/A

Study Design

  • Open Label

  • Multicenteric

  • Cohort

Phase

  • I

Study Id's

  • N/A

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved